In Vivo rapid delivery of vasopressin from an implantable drug delivery micro-electro-mechanical device
Keywords:
Subcutaneous drug delivery, vasopressin, MEMS, rabbit, bioavailabilityAbstract
A miniaturized implantable rapid drug delivery device based on microelectro-mechanical-systems technology was recently developed and characterized. This device is intended to address acute conditions in high-risk subjects. This work provides an in vivo proof-of-concept for the device in a rabbit model, by releasing a physiologically active dose of vasopressin, a vasoconstrictor. The devices were implanted subcutaneously and activated to rapidly release vasopressin, with monitoring of mean arterial pressure and plasma levels. Device releases showed a rapid and measurable effect on mean arterial pressure as well as a continuous diffusion of vasopressin into the bloodstream, consistent with a depot effect. Plasma levels in rabbits receiving vasopressin with the device rose monotonically to 24.4 ± 2.9 ng/mL after one hour. Bioavailability after one hour was calculated to be 6.2 ± 2.8 % (mean ± s.d.). A new modality for rapid and controlled drug delivery has been developed. The device can be used as a new implantable device controlled by medical algorithms (based on heart rate or mean arterial pressure, for example) for autonomous operation in high-risk populations that require immediate ambulatory intervention.
References
Li YW, Duc HLH, Tyler B, Williams T,
Tupper M, Langer R, Brem H, Cima MJ: In
vivo delivery of BCNU from a MEMS device
to a tumor model. Journal of Controlled
Release 2005;106:138-145.
Prescott JH, Lipka S, Baldwin S, Sheppard
NF, Maloney JM, Coppeta J, Yomtov B,
Staples MA, Santini JT: Chronic,
programmed polypeptide delivery from an
implanted, multireservoir microchip device.
Nature Biotechnology 2006;24:437-438.
Staples M, Daniel K, Cima MJ, Langer R:
Application of micro- and nanoelectromechanical devices to drug delivery.
Pharmaceutical Research 2006;23:847-863.
Elman NM, Patta Y, Scott AW, Masi B, Ho
Duc HL, Cima MJ: The next generation of
drug-delivery microdevices. Clin Pharmacol
Ther 2009;85:544-547.
Maloney JM, Uhland SA, Polito BF,
Sheppard NF, Pelta CM, Santini JT:
Electrothermally activated microchips for
implantable drug delivery and biosensing.
Journal of Controlled Release 2005;109:244-
Elman NM, Ho Duc HL, Cima MJ: An
implantable MEMS drug delivery device for
rapid delivery in ambulatory emergency care.
Biomed Microdevices 2009;11:625-631.
Cooney CG, Towe BC: A thermopneumatic
dispensing micropump. Sensors and Actuators
a-Physical 2004;116:519-524.
Jun DH, Sim WY, Yang SS: A novel constant
delivery thermopneumatic micropump using
surface tensions. Sensors and Actuators aPhysical 2007;139:210-215.
Jeong OC, Park SW, Yang SS, Pak JJ:
Fabrication of a peristaltic PDMS micropump.
Sensors and Actuators a-Physical 2005;123-
:453-458.
den Ouden DT, Meinders AE: Vasopressin:
physiology and clinical use in patients with
vasodilatory shock: a review. Netherlands
Journal of Medicine 2005;63:4-13.
Henderson KK, Byron KL: Vasopressininduced vasoconstriction: two concentrationdependent signaling pathways. J Appl Physiol
;102:1402-1409.
Holmes C, Landry D, Granton J: Science
Review: Vasopressin and the cardiovascular
system part 2 - clinical physiology. Critical
Care 2004;8:15-23.
Treschan TA, Peters J: The vasopressin
system - Physiology and clinical strategies.
Anesthesiology 2006;105:599-612.
2005 American Heart Association Guidelines
for Cardiopulmonary Resuscitation and
Emergency Cardiovascular Care - Part 7.2:
Management of Cardiac Arrest. Circulation
;112:IV-58-66.
Wenzel V, Krismer AC, Arntz HR, Sitter H,
Stadlbauer KH, Lindner KH, the European
Resuscitation Council Vasopressor during
Cardiopulmonary Resuscitation Study G: A
Comparison of Vasopressin and Epinephrine
for Out-of-Hospital Cardiopulmonary
Resuscitation. N Engl J Med 2004;350:105-
Krismer AC, Wenzel V, Voelckel WG,
Innerhofer P, Stadlbauer KH, Haas T, Pavlic
M, Sparr HJ, Lindner KH, Koenigsrainer A:
Employing vasopressin as an adjunct
vasopressor in uncontrolled traumatic
hemorrhagic shock - Three cases and a brief
analysis of the literature. Anaesthesist
;54:220-224.
Raedler C, Voelckel WG, Wenzel V, Krismer
AC, Schmittinger CA, Herff H, Mayr VD,
Stadlbauer KH, Lindner KH, Konigsrainer A:
Treatment of Uncontrolled Hemorrhagic
Shock After Liver Trauma: Fatal Effects of
Fluid Resuscitation Versus Improved
Outcome After Vasopressin. Anesthesia and
Analgesia 2004;98:1759-1766.
Sharma RM, Setlur R: Vasopressin in
hemorrhagic shock. Anesthesia and Analgesia
;101:833-834.
Tsuneyoshi I, Onomoto M, Yonetani A,
Kanmura Y: Low-dose vasopressin infusion
in patients with severe vasodilatory
hypotension after prolonged hemorrhage
during general anesthesia. Journal of
Anesthesia 2005;19:170-173.
Chow S (ed): Encyclopedia of
biopharmaceutical statistics. New York, NY,
Marcel Dekker, 2000.
Clausen W, De Gaetano A, Vølund A:
Within-patient variation of the
pharmacokinetics of subcutaneously injected
biphasic insulin aspart as assessed by
compartmental modelling. Diabetologia
;49:2030-2038.
Gin H, Hanaire-Broutin H: Reproducibility
and variability in the action of injected
insulin. Diabetes Metab 2005;31:7-13.
Guerci B, Sauvanet JP: Subcutaneous insulin:
pharmacokinetic variability and glycemic
variability. Diabetes Metab 2005;31:4S7-
S24.
King KA, Courneya CA, Tang C, Wilson N,
Ledsome JR: Pharmacokinetics of vasopressin
and atrial natriuretic peptide in anesthetized
rabbits. Endocrinology 1989;124:77-83.
Dworkin MJ, Carnochan P, Allenmersh TG:
Nitric-Oxide Inhibition Sustains VasopressinInduced Vasoconstriction. British Journal of
Cancer 1995;71:942-944.
Grzonka Z, Kasprzykowski F, Lubkowska L,
Darlak K, Hahn TA, Spatola AF: In vitro
degradation of some arginine-vasopressin
analogs by homogenates of rat kidney, liver
and serum. Peptide Research 1991;4:270-274.
